Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
about
A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual menEffects of tamsulosin on premature ejaculation in men with benign prostatic hyperplasiaMulticenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensiManagement of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasiaQuality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.Risk stratification for benign prostatic hyperplasia (BPH) treatment.The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy.Current pharmacotherapy of nocturia.Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia.α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.Tamsulosin versus transurethral resection of the prostate: effect on nocturia as a result of benign prostatic hyperplasia.Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.In vitroandin vivoevaluation of a hydrogel-based prototype transdermal patch system of alfuzosin hydrochloride
P2860
Q34038361-0D97C527-2D7F-4669-B866-FB9EED916CC9Q34198858-11D3210C-1FE9-40C6-A384-0722423C8603Q35001406-DE522434-9B0B-49F4-86D6-4EDDD3498844Q35737705-EA9519C5-DC6B-4A2E-886F-E9A32377DF78Q36820221-353AB0E0-2918-4B60-9055-AB407402714AQ37832294-68E133C5-4F6D-4C5E-A0A4-8C4D8E4E4628Q38077543-6B661510-B6FA-4B6B-9276-926821952B21Q38095986-0C5070DE-A675-42D9-B1DB-057BE1A8A049Q40202933-90BC7624-73DE-4932-9EC2-B716A7EDE4A6Q42934507-D224119A-E7D6-4526-A2DF-A6C7F23F9426Q44761271-F67B67E4-69C9-4723-B56B-3A163BB314C6Q48316264-929716FB-711C-41C4-BC6B-E0E613578F13Q53105128-55890F34-C701-4FCE-ADF3-5A6719CEB9FBQ53138146-491E1913-C73B-400C-821E-9DAA30B59D53Q56035520-27B94F8B-7EFB-4AD1-B44D-A426A2A6697A
P2860
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@en
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@nl
type
label
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@en
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@nl
prefLabel
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@en
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@nl
P2093
P2860
P1433
P1476
Alfuzosin 10 mg once daily for ...... erience in real-life practice.
@en
P2093
ALF-ONE Study Group
Antonio Alcaraz
Guy Vallancien
Haim Matzkin
Mostafa Elhilali
Niels Harving
R Jeroen A van Moorselaar
Rudolf Hartung
P2860
P304
P356
10.1111/J.1464-410X.2008.07458.X
P577
2008-04-01T00:00:00Z